With Ackman Out, Valeant Confronts Rocky Road to Revival

With Ackman Out, Valeant Confronts Rocky Road to Revival


Even before Valeant Pharmaceuticals International Inc. lost its most vocal cheerleader last week, with the exit of hedge-fund mogul Bill Ackman, Wall Street analysts were virtually unanimous: the company's old business model is broken. Growth, if there is any, will come slowly.



from Biotech News